Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
iOnctura
Ipsen
Merck Sharp & Dohme LLC
Lokon Pharma AB
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Corcept Therapeutics
Merck Sharp & Dohme LLC
Jiangsu HengRui Medicine Co., Ltd.
Merck Sharp & Dohme LLC
NGM Biopharmaceuticals, Inc
Orinove, Inc.
Merck Sharp & Dohme LLC
Kyntra Bio
US Oncology Research
Merck Sharp & Dohme LLC
Celgene
Lisata Therapeutics, Inc.
Bristol-Myers Squibb
Coherus Oncology, Inc.
Processa Pharmaceuticals
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Celgene
Hoffmann-La Roche
Kyntra Bio
Mereo BioPharma
Corcept Therapeutics
Merck Sharp & Dohme LLC
ERYtech Pharma
Merck Sharp & Dohme LLC
Cellectar Biosciences, Inc.
Hoffmann-La Roche
Panbela Therapeutics, Inc.
iOMEDICO AG
Merck Sharp & Dohme LLC
Eli Lilly and Company
Celgene
Theriva Biologics SL
Mereo BioPharma
Mereo BioPharma
Celgene
Halozyme Therapeutics
Celgene
Altor BioScience